TARS vs. DRUG

Last updated Jun 4, 2026

TARS (Tarsus Pharmaceuticals, Inc.) and DRUG (Bright Minds Biosciences Inc) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, TARS returned 11.64%/yr vs 26.80%/yr for DRUG. At a 0.12 correlation, their price movements are largely independent.

Performance

TARS vs. DRUG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Tarsus Pharmaceuticals, Inc. (TARS) and Bright Minds Biosciences Inc (DRUG). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, TARS achieves a -28.24% return, which is significantly lower than DRUG's -4.64% return.

TARS

• 1D: 2.35%
• 1M: -9.00%
• YTD: -28.24%
• 6M: -28.24%
• 1Y: 33.82%
• 3Y*: 51.02%
• 5Y*: 11.64%
• 10Y*: —

DRUG

• 1D: -3.07%
• 1M: -10.62%
• YTD: -4.64%
• 6M: 0.49%
• 1Y: 171.01%
• 3Y*: 193.95%
• 5Y*: 26.80%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

TARS vs. DRUG - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
TARS Tarsus Pharmaceuticals, Inc.	-28.24%	47.88%	173.43%	38.13%	-34.84%	-27.37%
DRUG Bright Minds Biosciences Inc	-4.64%	116.66%	2,418.88%	-61.35%	-76.66%	-41.30%

Correlation

The correlation between TARS and DRUG is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.21
Correlation (3Y) Calculated over the trailing 3-year period	0.14
Correlation (5Y) Calculated over the trailing 5-year period	0.12
Correlation (All Time) Calculated using the full available price history since Mar 23, 2021	0.12

Fundamentals

Market Cap TARS : $2.52B DRUG : $713.68M
EPS TARS : -$1.13 DRUG : -$3.48
PB Ratio TARS : 7.23 DRUG : 2.31
Total Revenue (TTM) TARS : $535.08M DRUG : $0.00
Gross Profit (TTM) TARS : $483.93M DRUG : -$20.13K
EBITDA (TTM) TARS : -$39.55M DRUG : -$31.36M

Return for Risk

TARS vs. DRUG — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TARS

TARS Risk / Return Rank: 64
TARS Sharpe Ratio Rank: 66
TARS Sortino Ratio Rank: 65
TARS Omega Ratio Rank: 60
TARS Calmar Ratio Rank: 64
TARS Martin Ratio Rank: 64

DRUG

DRUG Risk / Return Rank: 89
DRUG Sharpe Ratio Rank: 91
DRUG Sortino Ratio Rank: 88
DRUG Omega Ratio Rank: 84
DRUG Calmar Ratio Rank: 93
DRUG Martin Ratio Rank: 91

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TARS vs. DRUG - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Tarsus Pharmaceuticals, Inc. (TARS) and Bright Minds Biosciences Inc (DRUG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TARS	DRUG	Difference
Sharpe ratio: Return per unit of total volatility	0.77	2.39	-1.62
Sortino ratio: Return per unit of downside risk	1.48	3.06	-1.58
Omega ratio: Gain probability vs. loss probability	1.17	1.34	-0.18
Calmar ratio: Return relative to maximum drawdown	1.12	6.00	-4.88
Martin ratio: Return relative to average drawdown	2.57	13.58	-11.01
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TARS vs. DRUG - Sharpe Ratio Comparison

The current TARS Sharpe Ratio is 0.77, which is lower than the DRUG Sharpe Ratio of 2.39. The chart below compares the historical Sharpe Ratios of TARS and DRUG, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	TARS	DRUG	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.77	2.39	-1.62
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.20	0.04	+0.16
Sharpe Ratio (All Time) Calculated using the full available price history	0.32	0.03	+0.29

Drawdowns

TARS vs. DRUG - Drawdown Comparison

The maximum TARS drawdown since its inception was -77.67%, smaller than the maximum DRUG drawdown of -97.68%. Use the drawdown chart below to compare losses from any high point for TARS and DRUG.

Drawdown Indicators

	TARS	DRUG	Difference
Max Drawdown Largest peak-to-trough decline	-77.67%	-97.68%	+20.01%
Max Drawdown (1Y) Largest decline over 1 year	-30.42%	-28.69%	-1.73%
Max Drawdown (3Y) Largest decline over 3 years	-47.28%	-76.98%	+29.70%
Max Drawdown (5Y) Largest decline over 5 years	-71.29%	-97.68%	+26.39%
Current Drawdown Current decline from peak	-28.78%	-22.47%	-6.31%
Average Drawdown Average peak-to-trough decline	-40.62%	-59.03%	+18.41%
Ulcer Index Depth and duration of drawdowns from previous peaks	13.18%	12.65%	+0.53%

Volatility

TARS vs. DRUG - Volatility Comparison

The current volatility for Tarsus Pharmaceuticals, Inc. (TARS) is 13.29%, while Bright Minds Biosciences Inc (DRUG) has a volatility of 19.47%. This indicates that TARS experiences smaller price fluctuations and is considered to be less risky than DRUG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TARS	DRUG	Difference
Volatility (1M) Calculated over the trailing 1-month period	13.29%	19.47%	-6.18%
Volatility (6M) Calculated over the trailing 6-month period	28.45%	46.83%	-18.38%
Volatility (1Y) Calculated over the trailing 1-year period	44.27%	72.13%	-27.86%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	59.12%	662.71%	-603.59%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	63.95%	649.79%	-585.84%

Dividends

TARS vs. DRUG - Dividend Comparison

Neither TARS nor DRUG has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both TARS and DRUG in my portfolio?

TARS and DRUG have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, TARS or DRUG?

DRUG has higher volatility (19.47%) compared to TARS (13.29%). In terms of maximum drawdown, TARS dropped -77.67% vs DRUG's -97.68%.

Which has better risk-adjusted returns?

DRUG currently has the higher Sharpe Ratio (2.39 vs 0.77), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.